CCAM
MIST icon

Cascades Capital Asset Management’s Milestone Pharmaceuticals MIST Stock Holding History

Cascades Capital Asset Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,510
Closed -$157K – 171
2025
Q4 		$157K Buy
77,510
+175
+0.2% +$377 0.07% 134
2025
Q3 		$155K Buy
77,335
+10,200
+15% +$17.9K 0.07% 132
2025
Q2 		$130K Buy
+67,135
New +$89.5K 0.07% 131

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Cascades Capital Asset Management's MIST Position: Q1 2026 in Review

Cascades Capital Asset Management sold out of Milestone Pharmaceuticals (MIST) in Q1 2026, closing a stake of 77,510 shares — an estimated $157K sold.

Cascades Capital Asset Management first reported a position in MIST in Q2 2025 and held it in 3 quarters. The position peaked at $157K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Cascades Capital Asset Management reported no remaining Milestone Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cascades Capital Asset Management sold 77,510 Milestone Pharmaceuticals shares in Q1 2026, an estimated $157K.
  • Cascades Capital Asset Management first reported a position in Milestone Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Cascades Capital Asset Management's Milestone Pharmaceuticals position peaked at $157K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Cascades Capital Asset Management's 13F filing for Q1 2026, filed 15 May 2026.